Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
Tel Aviv, Israel / Vancouver, Canada, May 02, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:...
Pharmaceutical
Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET
ASHBURN, Va., May 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage...
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator
FARMINGTON HILLS, Mich., May 02, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused...
Nusano to Present Production Capabilities to European Radiopharmaceuticals Working Group
Proprietary ion source and beam technology capable of producing approximately 10 times the current global supply of Astatine-211WEST VALLEY CITY,...
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team...
New GIMOTI Patent Listed in FDA Orange Book
Broad Formulation Patent Expands Protection for GimotiSOLANA BEACH, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty...
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at...
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a...
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164
Submission of Investigational New Drug application expected in the second quarter of 2023 with start of Phase 1 trial expected...
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
BMF-500, a novel 3rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and...
CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional...
Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F Filing
MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a...
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused...
Ring Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategy
McNulty brings deep experience in capital formation and business development to Ring Follows recent appointment of Dr. Christopher Wright as...
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has...
Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023
RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing...
ODAIA Raises $25 Million in Series B Funding to Advance Its AI-Driven Commercial Insights Software for Pharma
With funding, ODAIA to fuel expansion and support the rapid growth of its AI-powered solutions that help pharma companies put...